Company: SINT
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024040
Chunk: 46

Company: Sintx Technologies, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 3
Chunk 46
---
Not
applicable.

ITEM
4. CONTROLS AND PROCEDURES

This
Report includes the certifications of our Chief Executive Officer and Principal Financial Officer required by Rule 13a-14 of the Securities
Exchange Act of 1934 (the “Exchange Act”). See Exhibits 31.1 and 31.2. This Item 4 includes information concerning the controls
and control evaluations referred to in those certifications.

Evaluation
of Disclosure Controls and Procedures

We
maintain disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act
of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed in the reports filed
or submitted under the Exchange Act, is recorded, processed, summarized, and reported within the time periods specified by the Commission’s
rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be
disclosed in our reports filed or submitted under the Exchange Act are properly recorded, processed, summarized and reported within the
time periods required by the Commission’s rules and forms.

We
carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer
(principal executive officer and principal financial officer), of the effectiveness of the design and operation of these disclosure controls
and procedures, as such term is defined in Exchange Act Rule 13a-15(e), as of June 30, 2025. Based on this evaluation, the Chief Executive
Officer concluded that our disclosure controls and procedures were effective as of June 30, 2025, the end of the period covered by this
Quarterly Report on Form 10-Q.

There
were no changes in our internal control over financial reporting that occurred during the second quarter of 2025 that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.

24

PART
II

ITEM
1. LEGAL PROCEEDINGS

We
are not aware of any pending or threatened legal proceeding against us that could have a material adverse effect on our business, operating
results or financial condition. The medical device industry is characterized by frequent claims and litigation, including claims regarding
patent and other intellectual property rights as well as improper hiring practices. As a result, we may be involved in various legal
proceedings from time to time.

Item
1A. Risk Factors